178 related articles for article (PubMed ID: 24344151)
1. Treating Clostridium difficile infection.
Shafran DM; Shafran SD
CMAJ; 2014 Apr; 186(7):531. PubMed ID: 24344151
[No Abstract] [Full Text] [Related]
2. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.
Johnson S; Gerding DN; Louie TJ; Ruiz NM; Gorbach SL
Antimicrob Agents Chemother; 2012 Aug; 56(8):4043-5. PubMed ID: 22615287
[No Abstract] [Full Text] [Related]
3. [Clostridium difficile infections - still a major challenge].
Strauss R; Neurath MF
MMW Fortschr Med; 2013 Apr; 155(7):57-9. PubMed ID: 23668179
[No Abstract] [Full Text] [Related]
4. Fecal transplantation therapy for Clostridium difficile-associated pouchitis.
Patel LN; Schairer J; Shen B
Int J Colorectal Dis; 2014 Feb; 29(2):263-4. PubMed ID: 24132529
[No Abstract] [Full Text] [Related]
5. Fidaxomicin: a review of its use in patients with Clostridium difficile infection.
Scott LJ
Drugs; 2013 Oct; 73(15):1733-47. PubMed ID: 24136090
[TBL] [Abstract][Full Text] [Related]
6. Fidaxomicin: in Clostridium difficile infection.
Duggan ST
Drugs; 2011 Dec; 71(18):2445-56. PubMed ID: 22141387
[TBL] [Abstract][Full Text] [Related]
7.
Mullish BH; Williams HR
Clin Med (Lond); 2018 Jun; 18(3):237-241. PubMed ID: 29858434
[TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea.
Clutter DS; Dubrovskaya Y; Merl MY; Teperman L; Press R; Safdar A
Antimicrob Agents Chemother; 2013 Sep; 57(9):4501-5. PubMed ID: 23836168
[TBL] [Abstract][Full Text] [Related]
9. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN
Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318
[TBL] [Abstract][Full Text] [Related]
10. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.
Eyre DW; Babakhani F; Griffiths D; Seddon J; Del Ojo Elias C; Gorbach SL; Peto TE; Crook DW; Walker AS
J Infect Dis; 2014 May; 209(9):1446-51. PubMed ID: 24218500
[TBL] [Abstract][Full Text] [Related]
11. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.
Mullane KM; Miller MA; Weiss K; Lentnek A; Golan Y; Sears PS; Shue YK; Louie TJ; Gorbach SL
Clin Infect Dis; 2011 Sep; 53(5):440-7. PubMed ID: 21844027
[TBL] [Abstract][Full Text] [Related]
13. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
15. Is fidaxomicin the drug of choice for treating Clostridium difficile-associated diarrhea in patients with cancer?
Green MR; Acharya UH; Yeager AM
J Clin Oncol; 2013 Dec; 31(34):4376-8. PubMed ID: 24166524
[No Abstract] [Full Text] [Related]
16. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences.
Johnson S; Gerding DN
Clin Infect Dis; 2013 Jan; 56(2):309-10. PubMed ID: 23024296
[No Abstract] [Full Text] [Related]
17. 'Game changer' antibiotic and others in works for superbug.
Dolgin E
Nat Med; 2011 Jan; 17(1):10. PubMed ID: 21217660
[No Abstract] [Full Text] [Related]
18. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
[TBL] [Abstract][Full Text] [Related]
19. Treatment of recurrent and severe Clostridium difficile infection.
Keller JJ; Kuijper EJ
Annu Rev Med; 2015; 66():373-86. PubMed ID: 25587656
[TBL] [Abstract][Full Text] [Related]
20. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.
Weiss K; Allgren RL; Sellers S
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S110-5. PubMed ID: 22752858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
